Market Overview - The biopharmaceutical sector experienced a decline of 1.05% on January 16, with Olin Bio leading the drop [1] - The Shanghai Composite Index closed at 4101.91, down 0.26%, while the Shenzhen Component Index closed at 14281.08, down 0.18% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Wanzhe Co., Ltd. (000534) with a closing price of 22.85, up 3.02% and a trading volume of 251,300 shares, totaling 589 million yuan [1] - Wendi Pharmaceutical (688488) closed at 21.60, up 2.96% with a trading volume of 289,600 shares, totaling 597 million yuan [1] - Sanofi Biopharmaceuticals (688336) closed at 58.88, up 2.56% with a trading volume of 47,400 shares, totaling 279 million yuan [1] - Major decliners included: - Olin Bio (6158888) closed at 24.75, down 15.21% with a trading volume of 189,400 shares, totaling 515 million yuan [2] - Kanglao Health (920575) closed at 9.81, down 5.40% with a trading volume of 139,800 shares, totaling 139 million yuan [2] - Dongbao Bio (300239) closed at 6.19, down 3.88% with a trading volume of 214,700 shares, totaling 135 million yuan [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 681 million yuan from institutional investors, while retail investors contributed a net inflow of 337 million yuan [2] - The capital flow for specific stocks showed: - Aidi Pharmaceutical (688488) had a net inflow of 37.04 million yuan from institutional investors, but a net outflow of 44.62 million yuan from retail investors [3] - Wanzhe Co., Ltd. (000534) had a net inflow of 29.97 million yuan from institutional investors, with a net outflow of 39.12 million yuan from retail investors [3] - Te Bao Bio (688278) had a net inflow of 4.89 million yuan from institutional investors, but a net outflow of 5.01 million yuan from retail investors [3]

格隆汇1月16日｜康乐卫士公告，近日，北京康乐卫士生物技术股份有限公司收到山西省疾病预防控制 中心发送的《关于暂停重组三价和重组九价人乳头瘤病毒疫苗Ⅲ期临床试验的函》及江苏省疾病预防控 制中心发送的《关于暂停重组九价人乳头瘤病毒疫苗Ⅲ期临床试验的函》。根据函件内容，由于公司临 床试验经费支付逾期，现场研究经费短缺，无法继续开展后续妇科访视工作。因此，山西省疾病预防控 制中心暂停公司重组三价人乳头瘤病毒疫苗和重组九价人乳头瘤病毒疫苗Ⅲ期临床试验，江苏省疾病预 防控制中心暂停公司九价HPV疫苗Ⅲ期临床试验。 ...

Core Viewpoint - The company is facing a suspension of its clinical trials for its HPV vaccines due to overdue payments for clinical trial funding and a shortage of on-site research funds [1] Group 1 - The Shanxi Provincial Center for Disease Control and Prevention has suspended the company's Phase III clinical trials for the trivalent HPV vaccine and the nine-valent HPV vaccine (female indications) [1] - The Jiangsu Provincial Center for Disease Control and Prevention has also suspended the company's Phase III clinical trial for the nine-valent HPV vaccine (female indications) [1]

（文章来源：证券日报） 证券日报网讯 1月15日，康乐卫士发布公告称，控股股东天狼星控股集团有限公司解除质押6000000 股，占其所持股份9.93%，占公司总股本2.14%，解除日期为2026年1月13日。 ...

Core Viewpoint - The company, 康乐卫士, has announced the suspension of its Phase III clinical trials for both the trivalent and nine-valent HPV vaccines due to overdue funding and insufficient on-site research funds, as communicated by health authorities in Shanxi and Jiangsu provinces [1][2] Group 1: Clinical Trial Suspension - The trivalent HPV vaccine (16/18/58 types) and the nine-valent HPV vaccine (6/11/16/18/31/33/45/52/58 types) clinical trials have been suspended due to overdue clinical trial funding [1] - The suspension is primarily due to the inability to continue gynecological visits necessary for the trials [1] Group 2: Impact on Clinical Trials - The trivalent HPV vaccine has already met the endpoint case collection requirements for its clinical protocol and is expected to have its market approval application accepted by April 2025, indicating that the suspension will not significantly impact this project [1] - The nine-valent HPV vaccine has completed the collection of cases for its primary endpoint and is currently in the process of accumulating secondary endpoint cases, but prolonged suspension may adversely affect this aspect [2] Group 3: Funding and Future Actions - The company is actively seeking funding through various channels to resolve overdue payments and resume normal clinical trial operations [2] - There is a risk that stakeholders may terminate the project if the company fails to make timely payments for overdue funding [2]

证券之星消息，1月15日生物制品板块较上一交易日下跌0.82%，康乐卫士领跌。当日上证指数报收于 4112.6，下跌0.33%。深证成指报收于14306.73，上涨0.41%。生物制品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 688488 | 文迪药业 | 20.98 | 5.80% | 21.79万 | | 4.54亿 | | 603087 | 日李药业 | 72.55 | 4.69% | 16.82万 | | 12.25亿 | | 688293 | 奥浦迈 | 58.73 | 3.78% | 2.06万 | | 1.20亿 | | 688278 | 特宝生物 | 76.18 | 1.65% | 3.44万 | | 2.62亿 | | 688331 | 荣昌生物 | 104.90 | 1.51% | 10.51万 | | 11.06亿 | | 000534 | 万泽股份 | 22.18 | 1.32% | 12.60万 | | 2.78亿 | | 3 ...

Market Performance - Major market indices opened mixed, with the Shanghai Composite Index slightly down at 4138.65 points, while the Shenzhen Component Index rose by 0.17% to 14194.11 points, and the ChiNext Index increased by 0.34% to 3333.17 points [1] Individual Stock Performance - A total of 2111 stocks rose at the open, with 13 stocks hitting the daily limit up. Notable performers included *ST Asia-Pacific with 8 consecutive limit ups, ST Keli Da with 6 limit ups in 5 days, and Sanwei Communication and Meinian Health both with 4 consecutive limit ups [1] - Conversely, 2518 stocks declined at the open, with 11 stocks hitting the daily limit down, including Huaxia Happiness and Kuaiyi Elevator [1] Price Continuity Statistics - Among stocks that hit the limit up yesterday, 10 stocks continued to hit the limit up today, including Sanbian Technology and Sanjiang Shopping. Stocks that opened lower included Xinganjiang, Kangle Weishi, and Jushen Shares, with declines of 11.62%, 9.92%, and 8.90% respectively [1] - From the stocks that hit the limit down yesterday, 8 stocks continued to hit the limit down today, including Kuaiyi Elevator and Zai Sheng Technology [1]

Market Overview - On January 13, major indices in China experienced collective adjustments, with the Shenzhen Component Index falling over 1% and the ChiNext Index dropping nearly 2%. The Shanghai Composite Index closed down 0.64%, the Shenzhen Component Index down 1.37%, and the ChiNext Index down 1.96%. The total trading volume in the Shanghai and Shenzhen markets reached 3.65 trillion yuan, an increase of 49.6 billion yuan compared to the previous trading day [1] - In the U.S. stock market, the three major indices also declined on January 13. The Dow Jones Industrial Average fell by 398.21 points to close at 49,191.99, a decrease of 0.80%. The S&P 500 Index dropped by 13.53 points to 6,963.74, down 0.19%, while the Nasdaq Composite Index decreased by 24.03 points to 23,709.87, a decline of 0.10% [1] Sector Performance - In the Chinese market, over 3,700 stocks declined, with the AI application concept sector rising against the trend, seeing over ten constituent stocks hitting the daily limit up. The AI medical concept remained active, while the power grid equipment sector strengthened in the afternoon. The retail sector also showed active performance. Conversely, the commercial aerospace and controllable nuclear fusion sectors experienced significant declines [1] - In the U.S., the performance of major indices reflected a general downward trend, indicating a cautious market sentiment [1] Commodity Prices - International oil prices rose on January 13. The price of light crude oil futures for February delivery on the New York Mercantile Exchange increased by $1.65 to $61.15 per barrel, a rise of 2.77%. The March delivery Brent crude oil futures price rose by $1.60 to $65.47 per barrel, an increase of 2.51% [2] Policy and Regulatory Updates - The Ministry of Commerce of China announced the continuation of anti-dumping duties on imported solar-grade polysilicon from the U.S. and South Korea, effective from January 14, 2026, for a period of five years [2] - The Ministry of Industry and Information Technology issued an action plan for the high-quality development of industrial internet platforms from 2026 to 2028, aiming for significant progress in platform development and resource connectivity by 2028 [3][4] Company-Specific Developments - The approval of NVIDIA to export its H200 AI chips to China is expected to restart shipments to Chinese customers. This decision will be overseen by the U.S. Department of Commerce, which will also impose a fee of approximately 25% on the related transactions [7]

康乐卫士1月13日交易公开信息 | 买/ 卖 | 会员营业部名称 | 买入金额（万元） | 卖出金额（万元） | | --- | --- | --- | --- | | 买一 | 甬兴证券有限公司宁波和源路证券营业部 | 1768.50 | 0.00 | | 买二 | 东方财富证券股份有限公司拉萨东环路第二证券营业 | 1078.75 | 1131.47 | | | 部 | | | | 买三 | 东方证券股份有限公司昆明白龙路证券营业部 | 996.27 | 0.00 | | 买四 | 东吴证券股份有限公司苏州相城采莲路证券营业部 | 846.11 | 0.00 | | 买五 | 华安证券股份有限公司郑州陇海路营业部 | 822.59 | 0.00 | | 卖一 | 国金证券股份有限公司成都武成大街证券营业部 | 14.34 | 2759.29 | | 卖二 | 国投证券股份有限公司广州东风中路证券营业部 | 0.84 | 1318.91 | | 卖三 | 东方财富证券股份有限公司拉萨东环路第二证券营业 | 1078.75 | 1131.47 | | | 部 | | | | 卖四 | 国信证券股份有限公司深圳 ...

每经讯，2026年1月13日，北交所上市公司康乐卫士（920575，收盘价：11.99元）登上龙虎榜，交易方式是连续竞价，披露原因 是当日收盘价涨幅达到29.90%，成交数量3511.98万股，成交金额4.02亿元。买一席位为甬兴证券有限公司宁波和源路证券营业 部，买入1768.5万元；卖一席位为国金证券股份有限公司成都武成大街证券营业部，卖出2759.29万元。 | | 2026-01-13康乐卫士 (920575) 龙虎榜 | | | | --- | --- | --- | --- | | 序号 | 交易营业部名称 | 买入金额(元) | 卖出金额(元) | | न्द्र ग | 用兴证券有限公司宁波和源路证券营业部 | 17684998.21 | 0 | | 址2 | 东方财富证券股份有限公司拉萨东环路第二证券营业部 | 10787525 | 11314658.06 | | ग्रें3 | 东方证券股份有限公司昆明白龙路证券营业部 | 9962715.23 | 0 | | 买4 | 东吴证券股份有限公司苏州相城采莲路证券营业部 | 8461071.27 | 0 | | ન્નેર | 华安证券股份有 ...